Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Wall Street cheers after the company announced a surprise change in the corner office. Here's what investors need to know.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-28 19:20:07.011955.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
After Nevro Corp. (NVRO +0.00%), a medical device company focused on pain management, shared a number of corporate updates with investors, its shares rose 35% as of 10:55 a.m. EDT on Wednesday.
Nevro announced the following corporate changes today:
A lot of these changes were made under the guidance of Broadfin Capital, which is a global equity healthcare manager that holds a significant amount of Nevro stock.
Check out the latest earnings call transcript for Nevro.
Here's the commentary that Michael DeMane, Nevro's Chairman of the Board, shared with investors regarding the management change:
On behalf of the Board and our entire company, I am excited to welcome Keith Grossman to the Nevro team. Keith brings over 30 years of experience in leading innovative medical technology companies through periods of strategic change to deliver growth and enhanced value for stockholders. As we look to the future, I am confident that under Keith's direction, Nevro will be well-positioned to capture a burgeoning market opportunity with its pioneering spinal cord stimulation (SCS) technology to treat chronic pain.
Keith Grossman appears to have a successful track record of value creation behind him, so it's understandable why traders are cheering today.
Nevro has come up short of analyst estimates on its last four earnings reports, so it's understandable why the Board felt that change was necessary.
Will the new CEO be able to turbocharge the company's growth rate and create shareholder value? Only time will tell. Since leadership changes can be difficult on employees and customers, I think that caution is warranted.